J&j

J&J Speeds Up Timeline for Coronavirus Vaccine
Risk & Compliance

J&J Speeds Up Timeline for Coronavirus Vaccine

After lagging behind other companies, J&J now expects to begin a late-stage study of its vaccine candidate in September.
By Matthew Heller | July 16, 2020
Read More
J&J Found Liable for Helping Cause Opioid Crisis
Risk & Compliance

J&J Found Liable for Helping Cause Opioid Crisis

In a landmark ruling, an Oklahoma judge said the firm's opioid sales practices were false and misleading, endangering the safety of Oklahomans.
By Matthew Heller | August 27, 2019
Read More
J&J Sales Increase 1.7% But Miss Estimates
Strategy

J&J Sales Increase 1.7% But Miss Estimates

Earnings jumped 19% to $3.81 billion in the fourth quarter, but sales were hit by slowing demand for medical devices.
By Matthew Heller | January 24, 2017
Read More